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Introduction
============

Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse effect of heparin. The initial description concerned arterial thrombosis during unfractionated heparin (UFH) therapy \[[@B1]\]. HIT subsequently has been associated with an increased risk of venous or arterial thrombosis \[[@B2]-[@B4]\]. The pathophysiology of HIT consists of the generation of anti-PF4/heparin antibodies, resulting in platelet and endothelial cell activation, leading to a procoagulant state \[[@B5]\]. Continuous veno-venous hemofiltration (CVVH) is widely used for renal replacement. Because UFH often is used as anticoagulation therapy, patients undergoing CVVH might be at risk for anti-PF4/heparin antibody generation or HIT. One clinical feature of HIT in this context could be repeated hemofiltration-filter clotting \[[@B6],[@B7]\]. In our surgical intensive care unit (ICU), we recently observed two cases of HIT responsible for repeated hemofiltration-filter clotting in the absence of typical thrombocytopenia \[[@B8]\] and we then systematically measured the plasma anti-PF4/heparin antibody concentration in all patients with repeated hemofiltration-filter clotting during CVVH, with no obvious cause. The purpose of this study was to report a series of patients in whom an anti-PF4/heparin antibody test was performed and to identify factors associated with a positive test in this particular setting in order to determine when one should perform the test.

Materials and methods
=====================

Patients
--------

Between 1 November 2004 and 1 May 2006, 87 patients underwent CVVH. Twenty-eight of these patients experienced repeated (≥ 2) hemofiltration-filter clotting before the scheduled end of the CVVH session (24 to 48 hours) with no obvious cause and anti-PF4/heparin antibodies were assayed. We reviewed the charts of these 28 patients. In accordance with French law, because of the retrospective nature of the study, no written consent was requested. The study was approved by our institutional review board. For each patient, general characteristics, platelet counts at various time points (admission, nadir \[lowest reported concentration\], day of anti-PF4/heparin antibody assay, and maximal count), and CVVH session duration and efficiency (assessed by the urea reduction ratio before/after each session) were recorded. The duration of CVVH sessions was obtained from the CVVH surveillance sheet, on which nurses routinely recorded data on an hourly basis. For each patient, an objective clinical probability scoring system was used to calculate the likelihood of HIT according to the Four T-score \[[@B9]\]. For this purpose, we attributed 1 point for the third item, \'Thrombosis\', considering that the hemofiltration-filter clotting was equivalent to a \'recurrent thrombosis\'.

Continuous veno-venous hemofiltration settings
----------------------------------------------

CVVH was performed using the Aquarius system (Aquarius; Edwards Lifesciences, Maurepas, France). Blood flow was set at 250 to 300 mL/minute, ultrafiltrate flow at 35 mL/kg per hour, and substitution solutions (Hemosol^®^or Prismasol^®^; Hospal, Lyon, France) were delivered 1/3 pre-filter and 2/3 post-filter. A dual-lumen 11.5-French catheter (Mahurkar™; Tyco Healthcare, Wollerau, Switzerland) was inserted into either the femoral or right internal jugular vein. To exclude catheter dysfunction, catheters were changed in all patients at least once before anti-PF4/heparin antibody assay.

Anticoagulation management
--------------------------

Before starting the CVVH session, the hemofiltration circuit was heparinized by priming with 10,000 IU of UFH (Héparine Choay^®^; Sanofi-Synthélabo, Paris, France) in 2,000 mL of saline solution. UFH then was continuously infused in the hemofiltration circuit to obtain an activated partial thromboplastin time (aPTT) ratio ranging between 1.2 and 2. The aPTT ratios were measured systematically from the arterial line. In the case of a positive PF4 test, UFH was replaced by danaparoid sodium (Orgaran^®^; Organon SA, Eragny-sur-Epte, France) using the manufacturer\'s recommendations to obtain a specific danaparoid anti-Xa activity of between 0.4 and 0.6 IU/mL.

PF4 test and heparin-induced platelet activation assay
------------------------------------------------------

Anti-PF4/heparin antibodies were measured by enzyme-linked immunoabsorbent assay (heparin-platelet factor 4-induced antibody, HPIA; Diagnostica Stago, Asnières, France) according to the manufacturer\'s recommendations. The anti-PF4/heparin antibody was considered positive (PF4^+^) when optical densities (ODs) were greater than 1 IU. For anti-PF4/heparin antibody-positive patients, a platelet-rich plasma (PRP) aggregation assay was performed. Briefly, a plasma sample was incubated with donor PRP and a therapeutic (0.5 to 1 IU/mL) or high (100 IU/mL) UFH concentration in an aggregometer (Chronolog 490; Kordia Life Sciences, Leiden, The Netherlands) at 37°C. Platelet aggregation was monitored for 20 minutes. Results were considered positive if the aggregation was greater than or equal to 20% with a therapeutic UFH concentration and absent with a high UFH concentration. Appropriate positive and negative controls (stored patient plasma) were run in parallel with plasma samples. Cross-reactivity with danaparoid sodium was recorded under the same conditions.

Statistical analysis
--------------------

Data are presented as median (interquartile range) and compared with a Mann-Whitney or a chi-square test. Patients were classified into two groups (PF4^+^and PF4^-^) according to anti-PF4/heparin antibody concentration. For PF4^+^patients, duration and efficiency of CVVH sessions under UFH and danaparoid were compared with a Wilcoxon rank test. A receiver operating characteristic (ROC) curve was used to determine the best cutoff value for CVVH duration to predict a PF4^+^test. All statistics were performed with the MedCalc^®^software (MedCalc Software, Mariakerke, Belgium). A *P*value of less than 0.05 was considered significant.

Results
=======

Patients\' characteristics
--------------------------

Among the 28 patients with unexplained hemofiltration-filter clotting, seven were anti-PF4/heparin antibody-positive. Baseline characteristics were not different between the two groups (PF4^+^or PF4^-^), except for a higher SAPS II (Simplified Acute Physiologic Score II) for PF4^-^patients (Table [1](#T1){ref-type="table"}). None of the patients had a Four T-score of less than 4, indicating that they all had an intermediate or high pre-test probability of HIT. A Four T-score of at least 7 had a positive predictive value of 100% and a negative one of 84% for the diagnosis of HIT, with a sensitivity of 43%. Four of the seven PF4^+^patients (Table [1](#T1){ref-type="table"}, \#1--4) also had a positive PRP aggregation assay and may be considered as having a very likely diagnosis of HIT \[[@B2],[@B6]\]. Among the seven patients with HIT, two also had a vascular thrombosis, leading to the diagnosis of HITTS (heparin-induced thrombocytopenia and thrombosis syndrome): one had an ischemic stroke (\#4) and the other one a pulmonary embolism (\#5).

###### 

Characteristics of the study population

                                                                                                                                       Time to onset, days               Platelet counts, 10^9^/L                 aPTT ratios                                                                                                      
  ---------------- ---- ----------- ------------- --------------- --------------- ------------------ ---------- ---------- ----------- --------------------- ----------- -------------------------- ------------- --------------- ------------- ---------- ---------------- --------------- ---------------- --------------------- ----------
  PF4^+^           1    M           54            34              12              Cardiac            No         Yes        Yes         8                     6           8                          22            42              10            5          1.2              50              14               1.18                  No
                   2    M           59            29              6               Cardiac            No         No         No          6                     6           9                          13            76              51            7          1.2              100             2                2.26                  No
                   3    M           63            50              13              Cardiac            Yes        Yes        Yes         9                     8           9                          28            101             20            7          1.3              33              4                2.68                  No
                   4    F           49            44              11              Cardiac            No         Yes        Yes         7                     7           8                          8             251             95            7          1.2              33              6                1.89                  Yes
                   5    M           62            86              16              Trauma             Yes        Yes        Yes         15                    13          14                         22            163             66            5          2.4              100             5                1.18                  Yes
                   6    M           55            52              12              Cardiac            No         Yes        Yes         10                    8           11                         26            144             200           4          1.9              100             2                2.00                  No
                   7    M           57            42              14              Cardiac            Yes        Yes        Yes         16                    15          20                         43            78              46            5          2.6              100             8                2.11                  No
                                                                                                                                                                                                                                                                                                                                   
  Total (n = 7)         6 M (86%)   57 (55--62)   44^a^(36--51)   12.5 (12--14)   6 cardiac (86%)    3 (43%)    6 (86%)    6 (86%)     9 (8--15)             8 (6--13)   9 (9--14)                  22 (18--28)   101 (77--158)   51 (26--88)   5 (5--7)   1.3 (1.2--2.4)   100 (50--100)   5^a^(2.5--7.5)   2.00^a^(1.36--2.22)   2 (40%)
                                                                                                                                                                                                                                                                                                                                   
  PF4^-^           8    F           78            64              11              Visceral           Yes        Yes        Yes         4                     2           5                          4             109             48            6          3.1              100             19               0.11                  Yes
                   9    M           51            51              8               Visceral           Yes        Yes        Yes         5                     5           5                          16            413             234           6          1.6              75              4                0.19                  No
                   10   M           58            65              19              Cardiac            Yes        Yes        Yes         3                     2           10                         26            214             42            6          1.2              67              10               0.40                  No
                   11   M           77            68              15              Cardiac            Yes        Yes        Yes         14                    14          24                         47            176             52            5          1.8              100             12               0.13                  Yes
                   12   M           78            56              16              Cardiac            No         Yes        Yes         4                     4           5                          15            100             22            5          1.7              100             12               0.26                  Yes
                   13   M           83            89              18              Cardiac            Yes        Yes        Yes         4                     3           5                          28            86              33            6          1.8              100             9                0.17                  Yes
                   14   M           78            59              11              Cardiac            Yes        Yes        Yes         5                     2           4                          14            141             31            6          1.8              100             10               0.07                  Yes
                   15   M           37            35              14              Trauma             Yes        Yes        Yes         9                     7           7                          25            146             63            4          1.1              25              7                0.09                  No
                   16   F           73            62              15              Cardiac            Yes        Yes        Yes         36                    36          39                         50            94              48            5          3.9              100             24               0.29                  Yes
                   17   M           79            59              10              Visceral           Yes        Yes        Yes         9                     9           9                          12            169             86            6          1.4              100             31               0.18                  Yes
                   18   M           60            49              10              Cardiac            No         No         Yes         5                     3           5                          14            60              39            5          1.3              100             24               0.09                  No
                   19   M           48            48              8               Visceral           Yes        Yes        Yes         6                     2           9                          27            258             167           6          1.8              100             24               0.08                  Yes
                   20   F           75            54              11              Visceral           Yes        Yes        Yes         6                     4           7                          12            86              21            6          1.9              100             4                0.34                  Yes
                   21   M           60            39              13              Cardiac            No         Yes        Yes         4                     3           5                          58            61              47            6          1.5              100             24               0.19                  No
                   22   M           75            56              13              Cardiac            Yes        Yes        Yes         19                    17          20                         37            105             45            5          1.2              25              8                0.83                  Yes
                   23   M           78            57              13              Cardiac            Yes        Yes        Yes         5                     4           6                          61            67              44            6          1.0              0               13               0.02                  No
                   24   M           64            73              14              Visceral           No         Yes        Yes         16                    16          16                         26            206             95            6          1.4              100             16               0.24                  No
                   25   M           38            71              20              Vascular           Yes        Yes        Yes         4                     4           4                          33            210             49            6          1.7              100             18               0.20                  No
                   26   M           69            66              13              Cardiac            Yes        Yes        Yes         5                     4           5                          11            140             48            6          1.1              25              6                0.51                  Yes
                   27   F           37            52              13              Cardiac            Yes        Yes        Yes         6                     5           9                          27            57              234           6          1.4              100             7                0.58                  No
                   28   M           75            44              10              Visceral           Yes        Yes        Yes         22                    20          24                         53            203             42            5          1.4              86              24               0.29                  Yes
                                                                                                                                                                                                                                                                                                                                   
  Total (n = 21)        17 M(81%)   73 (56--78)   57 (50--65)     13 (10--15)     12 cardiac (57%)   17 (81%)   20 (95%)   21 (100%)   5 (4--9)              4 (3--10)   7 (5--12)                  26 (14--39)   140 (86--204)   48 (41--69)   6 (5--6)   1.5 (1.3--1.8)   100 (73--100)   12 (7.5--24)     0.20 (0.10--0.32)     12 (57%)

Patients were classified into two groups (PF4^+^and PF4^-^) according to anti-PF4/heparin antibody concentration (optical density \[OD\] \> 1 IU or not). PF4^+^patients 1 to 4 also had a positive functional test for heparin-induced thrombocytopenia (platelet-rich plasma aggregation test). No differences between these four patients and the remaining three patients with a negative functional test were observed. The types of surgery for the two trauma patients were orthopedic and visceral for patient 5 and visceral surgery only for patient 15. Shock was defined as the need for vasopressor support. Time to onset is the time between intensive care unit (ICU) admission or continuous veno-venous hemofiltration (CVVH) or unfractionated heparin (UFH) and the day of anti-PF4/heparin antibody assay. The Four T-score was calculated by considering that hemofiltration-filter clotting did constitute a \'recurrent thrombosis\' (= 1 point) \[[@B9]\]. Results are expressed as median (first quartile to third quartile) or number. ^a^*P*\< 0.05. M, male; F, female; aPTT, activated partial thromboplastin time (observed during the continuous veno-venous hemofiltration session with hemofiltration-filter clotting); D~0~, day of admission; D~PF4~, day of anti-PF4/heparin antibody assay; MV, mechanical ventilation; PF4^-^, anti-PF4/heparin antibody-negative; PF4^+^, anti-PF4/heparin antibody-positive; SAPS II, Simplified Acute Physiologic Score \[[@B19]\]; SOFA, Sepsis-related Organ Failure Assessment \[[@B20]\].

Platelet counts
---------------

The platelet counts and platelet count variations did not differ between the two groups at any time point (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In four patients (one PF4^+^and three PF4^-^), the platelet count was higher than 100 × 10^9^/L the day of the anti-PF4/heparin antibody test (Table [1](#T1){ref-type="table"}).

###### 

Laboratory and continuous veno-venous hemofiltration (CVVH) parameters

                                                                 PF4^+^(n = 7)       PF4^-^(n = 21)      *P*value
  -------------------------------------------------------------- ------------------- ------------------- ----------
  Creatinine before first CVVH, μmol/L                           600 (247--742)      403 (312--441)      0.34
  Urea before first CVVH, mmol/L                                 17 (10--25)         15 (12--24)         0.91
  Number of CVVH sessions                                        5 (4--11)           5 (3--9)            0.65
  Mean CVVH duration^a^, hours                                   10.4 (9.6--18--4)   22.7 (15.7--22.3)   0.03
  Mean urea reduction ratios^a^, percentage                      17 (10--37)         44 (30--52)         0.04
  Platelet nadir, 10^9^/L                                        40 (24--46)         35 (17--43)         0.54
  Maximum platelet count, 10^9^/L                                324 (238--366)      286 (182--403)      0.81
  PF4 platelet count variation (D~0~-D~PF4~), percentage         59 (35--73)         56 (35--73)         0.98
  Maximum platelet count variation (D~0~-D~nadir~), percentage   77 (49--81)         79 (55--87)         0.81
  Mean minimum aPTT ratios^b^                                    1.20 (1.12--1.22)   1.35 (1.10--1.56)   0.35
  Mean maximum aPTT ratios^b^                                    1.85 (1.65--2.12)   2.19 (1.51--2.93)   0.35

Platelet count variations were calculated as follows: \[(platelet D~0~-- platelet D~x~)/platelet D~0~\] × 100, where platelet D~0~is the platelet count on admission and platelet D~x~is the platelet count on the day of anti-PF4/heparin antibody assay (D~PF4~) or the minimal platelet count (D~nadir~). Results are expressed as median (first quartile to third quartile). ^a^For PF4^+^patients, mean duration and efficiency of CVVH sessions before replacement of unfractionated heparin by danaparoid; ^b^means of minimum and maximum aPTT ratios observed during all the CVVH sessions before D~PF4~. aPTT, activated partial thromboplastin time (on heparin therapy during all continuous veno-venous hemofiltration sessions); PF4^-^, anti-PF4/heparin antibody-negative; PF4^+^, anti-PF4/heparin antibody-positive.

Continuous veno-venous hemofiltration sessions
----------------------------------------------

The main CVVH session characteristics are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. No significant difference was observed in terms of aPTT ratios, regardless of the value considered. The duration of CVVH sessions was significantly decreased in PF4^+^patients (Table [1](#T1){ref-type="table"}; *P*= 0.007). An inverse correlation was observed between the anti-PF4/heparin antibody concentration (OD) and the duration of CVVH sessions (*r*^2^= 0.24; *P*= 0.01). As CVVH session duration was the only parameter associated with positive antibodies, we assessed the most relevant duration to predict a positive test. The ROC curve analysis showed that 6 hours was the best cutoff to predict a positive anti-PF4/heparin antibody test (with a sensitivity of 71%, a specificity of 85%, and an area under the curve of 0.83) (Figure [1](#F1){ref-type="fig"}). The efficiency of CVVH sessions (assessed by the urea reduction ratio) was also decreased in PF4^+^patients (Figure [2](#F2){ref-type="fig"}). The use of danaparoid sodium as a replacement for UFH allowed the restoration of adequate CVVH duration (32 \[22 to 37\] hours; *P*\< 0.05) and efficiency (urea reduction 55% \[36% to 68%\]; *P*\< 0.03) for PF4^+^patients (Figure [2](#F2){ref-type="fig"}).

![Receiver operator characteristic curve for continuous veno-venous hemofiltration (CVVH) duration. A receiver operating characteristic curve was used to assess the best cutoff for time to hemofiltration-filter clotting to predict a positive PF4 test. The arrow shows that a 6-hour duration of CVVH session is the most accurate cutoff (sensitivity 71%, specificity 85%, and area under the curve 0.83).](cc6937-1){#F1}

![Duration and efficiency of continuous veno-venous hemofiltration (CVVH) sessions. Boxes represent medians, interquartile ranges, and 10th and 90th percentiles of mean duration of CVVH sessions (upper panel) and urea reduction ratios (\[(urea before -- urea after)/urea before\] × 100, lower panel) observed in PF4^+^(n = 7) and PF4^-^(n = 21) patients when using unfractionated heparin (50 and 132 sessions for PF4^+^and PF4^-^patients, respectively) and in PF4^+^patients when using danaparoid sodium for anticoagulation (17 sessions). \**P*\< 0.05 compared with PF4^+^(using a Mann-Whitney test); ^\#^*P*= 0.027 compared with PF4^+^(using a Wilcoxon rank test). There was no difference between PF4^-^and danaparoid CVVH durations (*P*= 0.17) or urea reduction (*P*= 0.27). PF4^-^, anti-PF4/heparin antibody-negative; PF4^+^, anti-PF4/heparin antibody-positive.](cc6937-2){#F2}

Discussion
==========

Repeated hemofiltration-filter clotting leading to anti-PF4/heparin antibody assay is frequent in our experience. We report a large proportion of patients with positive anti-PF4/heparin antibodies (7 out of 28). A CVVH session lasting less than 6 hours was associated with positive antibodies. As the aim of this study was not to assess the prevalence of HIT or positive anti-PF4/heparin antibodies in our overall ICU population, we did not measure anti-PF4/heparin antibody for patients without hemofiltration-filter clotting. However, it is unlikely that \'unselected\' patients would have a high rate of positive anti-PF4/heparin antibodies. Indeed, the incidence of HIT in intensive care patients is about 1% \[[@B6],[@B10]\]. Furthermore, to our knowledge there are no data in the literature to support routine anti-PF4/heparin antibody assays without a clinical suspicion of HIT or thrombosis/clotting on heparin therapy \[[@B2],[@B6]\].

We and others have already described cases of repeated hemofiltration-filter clotting associated with positive anti-PF4/heparin antibodies \[[@B7],[@B8]\]. However, such a large proportion of patients with positive anti-PF4/heparin antibodies was not expected and has not been previously reported. In their large cohort of 2,046 post-operative critically ill patients, Gettings and colleagues \[[@B10]\] reported only 19 (0.9%) patients with positive anti-PF4/heparin antibodies. The presence of positive antibodies may be an independent risk factor for thrombotic events, apart from the diagnosis of HIT \[[@B11]\], as anti-PF4/heparin antibodies are associated with dose-dependent activation of coagulation \[[@B12]\]. We therefore decided to use a high cutoff value for positive antibody OD (\> 1 IU). It should be emphasized that the anti-PF4/heparin antibody OD observed in our patients was inversely correlated with the CVVH session duration. The time to onset of hemofiltration-filter clotting appeared to be shorter in patients with higher anti-PF4/heparin antibody titer, possibly indicating more intense activation of coagulation.

Despite the high cutoff chosen to define positive antibodies, a large number of patients presented positive antibodies. This is probably related to our study population as the probability of HIT (or positive anti-PF4/heparin antibodies) depends on the population studied \[[@B2],[@B9],[@B13]\]. In our study, patients were highly selected and represented less than one third of all patients undergoing CVVH in our unit. Furthermore, complicated cardiac surgery patients account for the majority of our case mix and, together with orthopedic patients, are known to present the highest risk of positive anti-PF4/heparin antibodies \[[@B2],[@B14],[@B15]\].

We do not assume that all seven anti-PF4/heparin antibody-positive patients had true HIT, but the diagnosis of HIT was very likely in four of these seven patients and was probable in the remaining three patients according to published criteria \[[@B6]\]. Furthermore, a strong positive test result (OD \> 1) is associated with a high likelihood ratio for HIT \[[@B2]\]. The diagnosis of HIT is based on two aspects: clinical features, including the course of platelet count (with a greater than 50% decrease over a typical time scale \[[@B16]\]), and laboratory features, including confirmation tests \[[@B2],[@B17]\]. In our study population, the timing of HIT suspicion was within the usual range. Moreover, the Four T-scores \[[@B9]\], though not validated for ICU patients, indicated at least an intermediate risk for all patients. Although thrombocytopenia is the most common feature of HIT, it is also a very common finding in ICU patients and could be related to many causes, including CVVH itself. In fact, platelet counts were low in both groups (PF4^+^and PF4^-^). The time to clotting of the hemofiltration-filter therefore appeared to be the only factor associated with positive anti-PF4/heparin antibodies. Interestingly, the 6-hour cutoff reported here is consistent with the 7.5-hour interval before clotting observed by Samuelsson and colleagues \[[@B7]\].

Finally, although the diagnosis of HIT was not certain for all anti-PF4/heparin antibody-positive patients, replacement of UFH by danaparoid sodium allowed the restoration of CVVH duration and efficiency, supporting the clinical relevance of anti-PF4/heparin antibody assay in the case of repeated hemofiltration-filter clotting, at least in a surgical ICU patient population. Interestingly, the durations of CVVH sessions under danaparoid sodium we observed were close to those described by de Pont and colleagues \[[@B18]\]. In accordance with the latter authors, we did not observe any bleeding complications during danaparoid therapy. Furthermore, once the diagnosis of HIT is considered, all heparin exposure, including intravenous catheter locks, should cease.

Because of the retrospective nature of the study, we are not able to precisely determine the causes of hemofiltration-filter clotting in the remaining 21 patients with negative anti-PF4/heparin antibody. In particular, we did not perform PRP aggregation assays or serotonin release assays to search for HIT with an antigenic target different from PF4, nor did we assess the anti-thrombin III levels of these patients, but they had elevated aPTT ratios, indicating a certain activity of UFH. Further studies focusing on hemofiltration-filter clotting are needed to better describe this issue and the different factors associated with filter clotting (such as coagulation activation or abnormalities as well as CVVH settings or catheter dysfunction).

Conclusion
==========

We report a large proportion of anti-PF4/heparin antibody-positive patients in the case of repeated hemofiltration-filter clotting during CVVH, particularly when clotting occurred in less than 6 hours. In these cases, replacement of UFH by danaparoid sodium (or other agents such as citrate or saline flushes) may be useful.

Key messages
============

• Heparin-induced thrombocytopenia diagnosis and positive anti-PF4/heparin antibody were frequently observed in the case of repeated hemofiltration-filter clotting during continuous veno-venous hemofiltration (CVVH) under heparin.

• Hemofiltration-filter clotting in less than 6 hours was the best predictor of positive anti-PF4/heparin antibody, while platelet count and its variation were not associated with a positive test.

• The replacement of heparin by danaparoid sodium allowed the restoration of CVVH duration and efficiency in anti-PF4/heparin antibody-positive patients.

Abbreviations
=============

aPTT = activated partial thromboplastin time; CVVH = continuous veno-venous hemofiltration; HIT = heparin-induced thrombocytopenia; ICU = intensive care unit; OD = optical density; PF4^-^= anti-PF4/heparin antibody-negative; PF4^+^= anti-PF4/heparin antibody-positive; PRP = platelet-rich plasma; ROC = receiver operating characteristic; UFH = unfractionated heparin.
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